Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

CHEMTUBIO · Chemical interrogation of microtubule eraser enzymes

HORIZONStatus: SIGNED1 July 202630 June 2031EU funding €1,668,750Call ERC-2025-STG

Erasers of protein post-translational modifications are ubiquitous regulatory enzymes that control cellular function and are targeted for the treatment of disease. One key example are erasers of histone acetylation, where inhibitors have reached the clinic as cancer chemotherapy. Currently, however, multiple other erasers lack tools of study to determine their relevance and generate clinical candidate molecules. One main reason for this limitation is that erasers display multivalent substrate recognition mechanisms that are difficult to replicate with standard assays in vitro and can jeopardise data translation. I have recently developed a solution to detect histone deacetylase activity in situ not on peptides, as it commonly done, but on semi-synthetic protein substrates and complexes, and still applicable to in vitro screening. My preliminary data supports that this methodology can be applied as a more general strategy, enabling studies and drug development on erasers currently inaccessible. Moreover, it holds great potential to localise eraser activity in living systems and generate maps of enzyme action on endogenous biological structures. CHEMTUBIO aims to generalise in situ eraser activity detection through application to the erasers of tubulin tail detyrosination. These enzymes generate gradients of detyrosination across the cytoskeleton lattice through mechanisms unknown and, even though inhibitors are attractive to treat cardiac and neuronal disorders, no probes are available for further investigation. Here, we will address these knowledge gaps and provide in situ sensors and chemical probes to advance the therapeutic application of detyrosinase inhibition. Furthermore, CHEMTUBIO will develop semi-synthesis methods to allow the study of microtubule lumen modifications. Erasers of luminal acetylation are attractive targets against neuromuscular disease and cancer, and we will provide key mechanistic knowledge to boost future therapeutic developments.

Consortium · 1 organisation

coordinator

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

ES · €1,668,750

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.